Oxthera

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones.
 
Oxthera Portfolio Ysios Capital
 

Details

OxThera AB
Sturegatan 56
SE-114 36 Stockholm
Sweden
http://www.oxthera.com